Olema Pharmaceuticals, Inc. financial data

Symbol
OLMA on Nasdaq
Location
San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 16 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1057% % 15%
Debt-to-equity 11% % -10%
Return On Equity -43% % 11%
Return On Assets -39% % 10%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 87,156,961 shares 28%
Common Stock, Shares, Outstanding 81,376,449 shares 9.5%
Entity Public Float $243,100,000 USD -46%
Common Stock, Value, Issued $8,000 USD 14%
Weighted Average Number of Shares Outstanding, Basic 87,006,027 shares 48%
Weighted Average Number of Shares Outstanding, Diluted 87,006,027 shares 48%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $157,697,000 USD 27%
General and Administrative Expense $21,001,000 USD 18%
Operating Income (Loss) $178,698,000 USD -26%
Nonoperating Income (Expense) $16,247,000 USD 27%
Net Income (Loss) Attributable to Parent $162,451,000 USD -25%
Earnings Per Share, Basic -1.87 USD/shares 15%
Earnings Per Share, Diluted -1.87 USD/shares 15%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $48,301,000 USD -65%
Marketable Securities, Current $457,136,000 USD 55%
Cash, Cash Equivalents, and Short-term Investments $505,400,000 USD 16%
Assets, Current $515,452,000 USD 18%
Property, Plant and Equipment, Net $274,000 USD -63%
Operating Lease, Right-of-Use Asset $1,146,000 USD -13%
Other Assets, Noncurrent $15,000 USD -6.2%
Assets $533,430,000 USD 18%
Accounts Payable, Current $9,253,000 USD 107%
Employee-related Liabilities, Current $1,149,000 USD 935%
Liabilities, Current $51,802,000 USD 24%
Operating Lease, Liability, Noncurrent $69,000 USD -73%
Liabilities $54,871,000 USD 31%
Accumulated Other Comprehensive Income (Loss), Net of Tax $621,000 USD 334%
Retained Earnings (Accumulated Deficit) $597,557,000 USD -37%
Stockholders' Equity Attributable to Parent $478,559,000 USD 17%
Liabilities and Equity $533,430,000 USD 18%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $43,979,000 USD -87%
Net Cash Provided by (Used in) Financing Activities $222,000 USD -97%
Net Cash Provided by (Used in) Investing Activities $45,083,000 USD -124%
Common Stock, Shares Authorized 490,000,000 shares 0%
Common Stock, Shares, Issued 81,376,449 shares 9.5%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $88,840,000 USD -155%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $48,301,000 USD -65%
Deferred Tax Assets, Valuation Allowance $143,393,000 USD 37%
Deferred Tax Assets, Gross $143,888,000 USD 37%
Operating Lease, Liability $1,193,000 USD -17%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $161,973,000 USD -25%
Lessee, Operating Lease, Liability, to be Paid $1,241,000 USD -18%
Operating Lease, Liability, Current $1,124,000 USD -4.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two $69,000 USD -74%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,172,000 USD -5.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $48,000 USD -39%
Deferred Tax Assets, Operating Loss Carryforwards $91,771,000 USD 51%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Operating Lease, Payments $1,233,000 USD 6.1%
Additional Paid in Capital $1,075,487,000 USD 27%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $128,000 USD 45%
Share-based Payment Arrangement, Expense $17,586,000 USD -22%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%